TABLE 1.
Population, Treatment Regimens, and the Market Share Input
| Value | Sources, details, and assumptions | |
|---|---|---|
| Population parameters | ||
| US population 2022, n | 332,941,000 | US Census Bureau68 |
| Enrollee in a health care plan, n | 1,000,000 | Assumption |
| Population aged at least 50 years, % | 36.04 | US Census Bureau68 |
| Prevalence of nAMD in people aged at least 50 years, % | 1.20 | Rudnicka et al (2015)81 |
| Patients with 1-eye involvement, % | 83.5 | Zarbin et al (2020)69 |
| Proportion of patients on anti-VEGF therapy before launch of brolucizumab, % | 80 | Assumption |
| nAMD population on public insurance, % | 73 | Assumption based on Rao et al (2018)39 |
| Treatment regimens, dosage (packs/year for 1 eye) | ||
| Manufacturer regimen | ||
| Ranibizumab | 12 | 0.5 mg (0.05 mL) monthly6 |
| Aflibercept | 8.02 | 2 mg (0.05 mL)/4 weeks for the first 3 doses, followed by the same doses once every 8 weeks7 |
| Bevacizumab | 12 | 1.25 mg (0.05 mL) monthly14,28 |
| Brolucizumab | 7.01 | 6 mg/0.05 mL/4 weeks for the first 3 doses, followed by every 8-12 weeks (10 weeks taken for calculation)8 |
| Pro re nata | ||
| Ranibizumab | 6.9 | CATT RCT28,29 |
| Aflibercept | 5.1 | Veritti et al (AFFIRMED study)89 |
| Bevacizumab | 7.7 | CATT RCT28,29 |
| Brolucizumab | 7.13 | HAWK & HARRIER RCTs30-32 |
| Treat and extend | ||
| Ranibizumab | 8.00 | LUCAS RCT33 |
| Aflibercept | 8.00 | ATLAS RCT34 |
| Bevacizumab | 8.90 | LUCAS RCT33 |
| Brolucizumab | 7.13 | HAWK & HARRIER RCTs31,32,70 |
| Real-world evidence | ||
| Ranibizumab | 7.23 | Ciulla et al (2020)41; Rao et al (2018)39 |
| Aflibercept | 7.04 | Ciulla et al (2020)41; Rao et al (2018)39 |
| Bevacizumab | 6.91 | Ciulla et al (2020)41; Rao et al (2018)39 |
| Brolucizumab | 5.55 | Bilgic et al (2021) (REBA study)71 |
| Market shares, % | ||
| Anti-VEGF market shares before brolucizumab launch | ||
| Ranibizumab | 24.56 | Parikh et al (2018)72; Ciulla et al (2020)41; Rao et al (2018)39 |
| Aflibercept | 17.48 | Parikh et al (2018)72; Ciulla et al (2020)41; Rao et al (2018)39 |
| Bevacizumab | 57.96 | Parikh et al (2018)72; Ciulla et al (2020)41; Rao et al (2018)39 |
| Brolucizumab uptake in 1 year after launch | ||
| Brolucizumab uptake in 1 year after launch | 3.84 | Zarbin et al (2020)69 |
| Percentage of Brolucizumab-switch | 92.51 | Zarbin et al (2020)69 |
| Percentage of Brolucizumab-naive | 7.49 | Zarbin et al (2020)69 |
| Proportion of switch from anti-VEGF to brolucizumab | ||
| Ranibizumab to brolucizumab | 15.41 | Zarbin et al (2020)69 |
| Aflibercept to brolucizumab | 71.15 | Zarbin et al (2020)69 |
| Bevacizumab to brolucizumab | 13.44 | Zarbin et al (2020)69 |
| Anti-VEGF market shares after brolucizumab launched (switch patients) | ||
| Ranibizumab | 24.01 | Calculated from input data |
| Aflibercept | 14.95 | Calculated from input data |
| Bevacizumab | 57.48 | Calculated from input data |
| Brolucizumab | 3.56 | Calculated from input data |
nAMD = neovascular age-related macular degeneration; RCT = randomized clinical trial; VEGF = vascular endothelial growth factor.